|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Finally, we observed increased HLA-B levels in correlation with tumor infiltration across the TCGA lung cancer cohorts.
|
30833945 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We demonstrated strong association of cervical neoplasia with risk and protective HLA haplotypes that are determined by the amino-acids carried at positions 13 and 71 in pocket 4 of HLA-DRB1 and position 156 in HLA-B.
|
28806749 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this report we describe a case of somatic mutation in the HLA-B gene in the tumour cells of a patient with acute myelogenous leukaemia (AML).
|
27297335 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Decreased expression of HLA-A (SCC <i>P</i> < 0.001), HLA-B/C (SCC <i>P</i> < 0.01; AC <i>P</i> < 0.01) and total classical HLA (SCC <i>P</i> < 0.001; AC <i>P</i> = 0.02) was apparent in metastatic tumor cells compared to the primary tumor.
|
27895918 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A general strategy to optimize immunogenicity of HLA-B*0702 restricted cryptic peptides from tumor associated antigens: Design of universal neo-antigen like tumor vaccines for HLA-B*0702 positive patients.
|
27506946 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.
|
18820911 |
2009 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HLA-B alleles, high-risk HPV infection and risk for cervical neoplasia in southern Chinese women.
|
16206270 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Identification of a MAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-B*5701 tumors.
|
15104676 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site.
|
12591737 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Down-regulation of HLA-B/C expression correlated with a lower tumor stage (p < 0.001) and a longer disease-free survival (p = 0.04).
|
12480922 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Significantly (p < 0.05) lower levels of HLA-B antigens were also detected on cells from solid malignancies of different histotypes but not on neoplastic cells from hemopoietic neoplasms; levels of HLA-B antigens were rapidly up-regulated by IFN-gamma exclusively on non-hemopoietic transformed cells.
|
11251973 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The identification of T cell epitopes presented by alternative HLA-B and -C alleles may provide a means to counteract the tumor escape mechanism based on the selection of tumor cells no longer susceptible to HLA-A-restricted T cell recognition.
|
9973437 |
1999 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Selective underexpression was detected in 1 tumor for HLA-A locus antigens and in 3 tumors for HLA-B locus antigens.
|
1849792 |
1991 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The expression of HLA class I antigens was studied in 99 primary tumour (colorectal, gastric and laryngeal carcinomas) and 57 autologous metastases using immunohistological techniques and monoclonal antibodies against class I monomorphic determinants, HLA-B isotypic determinants and HLA polymorphic determinants.
|
2649129 |
1989 |